News

Packaging Error Spurs Nationwide Recall of Generic OC


 

Seven lots of oral contraceptives containing norgestimate and ethinyl estradiol have been recalled nationwide because of a packaging error that could result in suboptimal protection against pregnancy, according to an announcement Feb. 27 by the Food and Drug Administration.

A statement on the agency's MedWatch site said that as a result of the packaging error in these lots, “the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.” The FDA advised that women who have been “exposed to” the affected packaging should start using a nonhormonal form of contraception immediately and those who have the product should return it to the pharmacy and contact their physician.

The affected OCs, manufactured by Glenmark Generics, were distributed to wholesalers and retail pharmacies nationwide between Sept. 21, 2011, and Dec. 30, 2011, and contain the following doses of norgestimate and ethinyl estradiol: 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.25 mg/0.035 mg.

The packaging error that prompted the recall is described as select blisters that are rotated 180 degrees within the card, which reverses the weekly tablet orientation and makes the lot number and expiration date visible on the outer pouch only, according to the FDA.

A statement issued by Glenmark said the following lot numbers are affected: 04110101, 04110106, and 04110107, with the expiration date of 7/31/2013; 04110114, 04110124, and 04110129, with the expiration date of 8/31/2013; and 04110134, with the expiration date of 9/30/2013.

Adverse events that may be related to the use of these products should be reported to Glenmark Generics, 888-721-7115 (8 a.m. to 5 p.m. ET Monday through Friday), or to the FDA's MedWatch Program anytime by faxing 800-332-1078 or visiting www.fda.gov/medwatch/report.htm

In the recalled lots, blisters rotated 180 degrees in the card reverse tablet orientation.

Source Courtesy U.S. Food and Drug Administration

Recommended Reading

Progesterone Quells Some Intractable Catamenial Seizures
MDedge Endocrinology
Obesity, Estrogen Status Sway Breast Ca Outcomes
MDedge Endocrinology
Girls With PCOS Prone to CVD, Diabetes
MDedge Endocrinology
Flaxseed Bars Found Ineffective for Hot Flashes
MDedge Endocrinology
Denosumab Not Cost Effective in Some Cancers
MDedge Endocrinology
Nonhormonal Meds Aid Hot Flashes in Breast Ca
MDedge Endocrinology
Endometriosis Treatment May Boost Migraine Risk
MDedge Endocrinology
Estradiol May Reduce Perimenopausal Depression
MDedge Endocrinology
Gabapentin Improves Hot Flashes, Sleep Post Menopause
MDedge Endocrinology
In PCOS, 10 Days of Clomiphene Better Than 5
MDedge Endocrinology